Anticipating drug resistance in the MAP kinase pathway

Pigment Cell and Melanoma Research

Volumn 23, Issue 1, 2010, Pages 7-9

  Marmorstein, Ronen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; B RAF KINASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE;

ALLELE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DROSOPHILA MELANOGASTER; HUMAN; MELANOMA; MUTAGENESIS; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES;

EID: 74349087121     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00657.x     Document Type: Short Survey

References (4)

1. McCubrey, J.A., Steelman, L.S., Chappell, W.H. et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263 1284.
2. Smalley, K.S. Flaherty, K.T. (2009). Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br. J. Cancer 100, 431 435.
3. Volpe, G., Panuzzo, C., Ulisciani, S. Cilloni, D. (2009). Imatinib resistance in CML. Cancer Lett. 274, 1 9.
4. Zhang, J., Yang, P.L. Gray, N.S. (2009). Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28 39.